Early-stage drugmakers face difficult decisions as public markets turn hostile
Author of the article:
Financial Times
Nicholas Megaw and Jamie Smyth in New York
Almost 200 listed biotechs globally are trading below the value of their cash reserves. Photo by PATRICK HERTZOG/AFP via Getty Images files As Genocea Biosciences Inc. ran low on cash in 2018, investors offered the biotech a lifeline that allowed it to shift focus from developing a vaccine for genital herpes to targeting cancer treatments. There was no such safety net in May, when another cash crunch forced the 16-year-old group to fold.
Advertisement 2 This advertisement has not loaded yet, but your article continues below.
“A year ago, Genocea probably could have raised enough cash to stay afloat until it could finish trials on its personalized cancer medicines,” said Daina Graybosch, analyst at SVB Securities LLC. Now, however, “the world has changed for biotech companies.”
The fate of Genocea captures the stark predicament facing a biotech sector accustomed to record-low interest rates, a bull run in equity markets and freewheeling investors. While the rupture with the era of easy money has hit almost every sector, few are as exposed as the early-stage drug companies that rely on capital markets to fund long and risky development cycles.
Almost 200 listed biotechs globally are trading below the value of their cash reserves, according to investment bank Torreya Capital, and more are now swallowing draconian deals to survive as the funding drought in public markets deepens.
Advertisement 3 This advertisement has not loaded yet, but your article continues below.
Just nine biotech companies have listed in the United States this year, raising a total of US$1 billion, according to LifeSci Capital LLC, a boutique investment bank. Almost 60 companies did so in the same period last year, tapping investors for US$7.4 billion.
“For many public company biotech CEOs looking to raise capital, it may feel like they are caught in the Sahara Desert. There is no money to be found,” said Torreya managing director Tim Opler.
San Diego, Calif.-based Belite Bio Inc. was one of the few to pull off an initial public offering. The company, which develops drugs targeting age related diseases such as diabetes, raised US$41 million in April and its stock has surged after U.S. regulators fast tracked one of its treatments. But chief executive Tom Lin said he only had the confidence to push ahead with the listing because its largest shareholder was prepared to back it.
Advertisement 4 This advertisement has not loaded yet, but your article continues below.
“We were actually quite nervous. The bankers tried to prepare us, letting us know we might not get enough investors or a good price,” he said. “(But) the most important thing was our existing shareholders are very confident about our pipeline … they participated in the IPO as well with a US$15-million investment, and that gave confidence for new investors.”
There is no money to be found
Tim Opler
For listed biotechs unable to lean on existing investors, the remaining choices include raising equity at huge discounts, taking out risky loans, monetizing future royalty streams and partnering with or being bought out by Big Pharma.
“What we’ve seen in the few follow-ons that are getting done are draconian pricing terms, warrant deals coming back and low valuations,” said Mark Charest, a portfolio manager at LifeSci Fund Management LLC.
Advertisement 5 This advertisement has not loaded yet, but your article continues below.
More than half of the listed companies that have completed follow-on fundraisings this quarter offered investors incentives to back their deals.
Others have turned to debt providers despite lacking the revenues to repay loans. Madrigal Pharmaceuticals Inc. last month secured a debt facility worth up to US$250 million to help commercialize its most advanced drug candidate and finance a clinical development program for another.
The abrupt change in the funding climate is not without winners, including companies such as Royalty Pharma PLC, which lends to biotechs in exchange for a share of future revenues.
While the Nasdaq Biotechnology index has tumbled 26 per cent this year and the broader S&P 500 is down 23 per cent, Royalty’s shares are flat. Last month, Royalty lifted to US$2.5 billion from US$1.5 billion the amount it intends to deploy annually for the next five years, in part to capitalize on the deteriorating outlook for many biotechs.
Advertisement 6 This advertisement has not loaded yet, but your article continues below.
For some companies, however, even the most expensive funding options will prove elusive, and more are likely to follow Genocea into collapse.
“Quality (of biotechs on public markets) is lower in part because of the promiscuous capital markets” of the past two years, LifeSci’s Charest said.
Many went public before reaching key development milestones that would have given a clearer indication of their chances of ultimate success, leading to a string of disappointing clinical readouts that have made it even harder to raise cash.
“If you fund the five best ideas out there the majority will probably do pretty well. If you fund 500, the number that don’t do well will be substantially higher,” Charest added.
Biotechs endured testing periods during the bull run that followed the 2008 financial crisis. The S&P Biotech index went into correction — a more than 10 per cent decline from recent highs — in 2015 and 2018, but industry executives say this slowdown is far more severe.
Advertisement 7 This advertisement has not loaded yet, but your article continues below.
“This is the worst level of distress I have seen in the industry for the past 25 years,” said Pierre Jacquet, managing director of L.E.K. Consulting LLC’s health-care division. “It’s a perfect storm and it is likely that tens of companies will just return cash to investors. I just don’t see any alternative exit for some of these companies.”
This is the worst level of distress I have seen in the industry for the past 25 years
Pierre Jacquet
Last week Zosano Pharma Corp., a California-based group developing a migraine drug delivery patch, filed for bankruptcy protection. In another sign of the stresses, the top shareholder in Forte Biosciences Inc., which develops drugs targeting autoimmune diseases such as alopecia, called for management to wind up the company and return its cash.
Early-stage drug companies are particularly vulnerable to the market turmoil because there are few easy ways for them to generate revenue or cut costs while conducting expensive clinical trials. The sector’s woes also provide a glimpse of the pressures that could face more companies if the strains do not ease.
Advertisement 8 This advertisement has not loaded yet, but your article continues below.
Senior bankers and lawyers are divided over whether stock markets will calm enough for IPOs to return en masse this year, but even the more sanguine do not expect to see a significant uptick in activity before the traditionally quiet midsummer period.
“Part of the discussion (with IPO candidates) now is, ‘What’s your bridge if the IPO timeline doesn’t work?’” said a senior capital markets lawyer. “A year ago, if a company said they wanted to list ‘right now,’ you could aim to be public in three to six months. Now you have to ask, ‘What’s your cash bridge for the next year?’”
Tablets on the production line of Bristol-Myers Squibb’s pharmaceutical plant of French group UPSA. Photo by GEORGES GOBET/AFP/Getty Images files Conditions are slightly less onerous for those biotechs yet to go public, giving them at least the option of trying to tap interest from a private equity industry still flush with funds. The appetite was underlined by buyout firm Apollo Global Management Inc.’s purchase last month of a stake in Sofinnova Partners SAS, a European venture capital firm specializing in life sciences.
Advertisement 9 This advertisement has not loaded yet, but your article continues below.
“It is quite striking that Blackstone, Carlyle and Apollo have all gotten into biotech and I’m sure there’ll be plenty more coming. It really reflects the mainstreaming of biotech as an asset class,” Torreya’s Opler said.
There have been about 120 private fundraisings worth US$9 billion this year, according to LifeSci, down roughly 30 per cent from the comparable period last year.
This month Mineralys Therapeutics Inc. raised US$118 million, led by European private-equity firm Andera Partners and RA Capital Management LP, a Boston-based investment manager. The Philadelphia-based biotech is developing a novel treatment for high blood pressure, a condition that affects nearly half of all U.S. adults, meaning a breakthrough treatment could prove a blockbuster drug.
Advertisement 10 This advertisement has not loaded yet, but your article continues below.
“There is still finance available for companies, which have good assets, can generate short-term news flow or are capitalized well enough to get to the next de-risking event,” said LEK’s Jacquet.
More On This Topic What new investors should consider before diving into their first account Nearly all of Wall Street – and the U.S. Federal Reserve – botched calls for 2022 Bankers predict lack of IPOs, share sales to persist until inflation, market volatility cools Some have also drawn the attention of Big Pharma, which SVB Securities estimates has up to US$500 billion to deploy on M&A due to the windfall from the coronavirus pandemic.
Bristol-Myers Squibb Co. earlier this month agreed to buy Turning Point Therapeutics Inc., which is developing a new cancer drug, for US$4.1 billion.
This advertisement has not loaded yet, but your article continues below.
Article content Nevertheless, most deals have been linked to promising drug pipelines rather than rescue of cash-strapped startups. There is little evidence that the steep drop in valuations is set to reignite M&A in a sector where dealmaking sank to its lowest level in a decade in 2021.
“We always follow the science,” said Eliav Barr, global head of clinical development and chief medical officer at Merck & Co. Inc., pointing out that the appeal of a target lies with the drug or treatment it is working on, not the collapse in its share price.
“If you go down to the bargain basement, to the ‘for sale’ rack for a discount of 50 per cent, well there may be a reason why that is so,” Barr said. “Just because it is cheap does not mean it is good for the company.”
The Financial Times Ltd.
_____________________________________________________________
If you like this story, sign up for the FP Investor Newsletter.
_____________________________________________________________
Financial Post Top Stories Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.
By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300